Riehen, Switzerland

Karl Vogler

This inventor holds 2 USPTO granted patents. Top assignee: Hoffmann-La Roche Inc.. Active years: 1976.


% Patents Active = 100.0

Average Co-Inventor Count = 4.0

ph-index = 2

Forward Citations = 5(Granted Patents)


Company Filing History:


Years Active: 1976

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Karl Vogler: Innovator in Antibiotic Development

Introduction

Karl Vogler is a notable inventor based in Riehen, Switzerland. He has made significant contributions to the field of pharmaceuticals, particularly in the development of antibiotics. With a total of 2 patents to his name, Vogler's work has had a meaningful impact on medical science.

Latest Patents

Vogler's latest patents include innovative compounds that are useful as antibiotics. One of his patents focuses on 6-acyl derivatives of aminopenicillanic acid. These compounds are represented by a specific formula wherein A is a substituted or unsubstituted heterocyclic radical, and T is a C2-C5 alkyl, alkenyl, cyclopropylmethyl, cyclobutylmethyl, or cyclopentyl group. The patent also discloses a process for their preparation and novel intermediates. Another patent involves furan, benzofuran, and tetrahydrofuran carboxylic acid esters, which are similarly represented by a specific formula and are also aimed at antibiotic development.

Career Highlights

Karl Vogler is associated with Hoffmann-La Roche Inc., a leading company in the pharmaceutical industry. His work at this esteemed organization has allowed him to focus on innovative solutions in antibiotic research.

Collaborations

Vogler has collaborated with notable coworkers such as Peter Quitt and Andre Furlenmeier. Their combined expertise has contributed to the advancement of antibiotic compounds.

Conclusion

Karl Vogler's contributions to antibiotic development through his patents and collaborations highlight his importance in the field of pharmaceuticals. His innovative work continues to pave the way for advancements in medical treatments.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…